Published in Semin Oncol on October 01, 2002
Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev (2006) 5.08
Studies on anticancer activities of antimicrobial peptides. Biochim Biophys Acta (2007) 3.24
Membrane-active host defense peptides--challenges and perspectives for the development of novel anticancer drugs. Chem Phys Lipids (2011) 1.45
Efficacy of goshajinkigan for peripheral neurotoxicity of oxaliplatin in patients with advanced or recurrent colorectal cancer. Evid Based Complement Alternat Med (2011) 1.31
Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer. Br J Cancer (2004) 1.27
A novel behavioral assay for measuring cold sensation in mice. PLoS One (2012) 1.27
The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen. Int J Clin Oncol (2011) 1.13
Neurotoxicity caused by the treatment with platinum analogues. Chemother Res Pract (2011) 1.12
Nanocarriers for delivery of platinum anticancer drugs. Adv Drug Deliv Rev (2013) 1.11
Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Arch (2006) 1.09
Adverse event profiles of platinum agents: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations. Int J Med Sci (2011) 1.09
Metastatic colorectal cancer-past, progress and future. World J Gastroenterol (2007) 1.04
Hemolytic uremic syndrome following the infusion of oxaliplatin: case report. BMC Clin Pharmacol (2006) 1.00
Oxaliplatin-DNA adduct formation in white blood cells of cancer patients. Br J Cancer (2008) 0.94
Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity. PLoS One (2011) 0.92
Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication. Support Care Cancer (2006) 0.89
UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer. Br J Cancer (2004) 0.89
Analgesic Effects of Bee Venom Derived Phospholipase A(2) in a Mouse Model of Oxaliplatin-Induced Neuropathic Pain. Toxins (Basel) (2015) 0.89
Review of systemic therapies for locally advanced and metastatic rectal cancer. J Gastrointest Oncol (2015) 0.88
Cellular uptake and cytoplasm / DNA distribution of cisplatin and oxaliplatin and their liposomal formulation in human colorectal cancer cell HCT116. Invest New Drugs (2010) 0.86
L type Ca²+ channel blockers prevent oxaliplatin-induced cold hyperalgesia and TRPM8 overexpression in rats. Mol Pain (2012) 0.85
Oxaliplatin-Related Ocular Toxicity. Case Rep Oncol (2010) 0.84
Systemic treatment-induced gastrointestinal toxicity: incidence, clinical presentation and management. Ann Gastroenterol (2012) 0.81
Membrane transporters as mediators of Cisplatin effects and side effects. Scientifica (Cairo) (2012) 0.81
Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study. Cancer Chemother Pharmacol (2009) 0.80
Conus vexillum venom induces oxidative stress in Ehrlich's ascites carcinoma cells: an insight into the mechanism of induction. J Venom Anim Toxins Incl Trop Dis (2013) 0.79
Preparation and In Vivo Evaluation of Dichloro(1,2-Diaminocyclohexane)platinum(II)-Loaded Core Cross-Linked Polymer Micelles. Chemother Res Pract (2012) 0.79
A rare case of acute kidney injury associated with autoimmune hemolytic anemia and thrombocytopenia after long-term usage of oxaliplatin. Clin Exp Nephrol (2012) 0.79
Management of locally advanced and metastatic colon cancer in elderly patients. World J Gastroenterol (2014) 0.79
Houttuynia cordata Thunb reverses oxaliplatin-induced neuropathic pain in rat by regulating Th17/Treg balance. Am J Transl Res (2016) 0.78
Oxaliplatin-Induced Tonic-Clonic Seizures. Case Rep Oncol Med (2015) 0.78
Sarcoidosis associated with oxaliplatin-based chemotherapy for colorectal cancer. Case Rep Oncol Med (2014) 0.78
Molecular mechanism of adenomatous polyposis coli-induced blockade of base excision repair pathway in colorectal carcinogenesis. Life Sci (2015) 0.77
Oxaliplatin-Induced Peripheral Neuropathy via TRPA1 Stimulation in Mice Dorsal Root Ganglion Is Correlated with Aluminum Accumulation. PLoS One (2015) 0.77
A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer. Support Care Cancer (2014) 0.76
The clinical analysis of acute pancreatitis in colorectal cancer patients undergoing chemotherapy after operation. Onco Targets Ther (2015) 0.75
Role of transporters in the distribution of platinum-based drugs. Front Pharmacol (2015) 0.75
Preventive Effects of Bee Venom Derived Phospholipase A₂ on Oxaliplatin-Induced Neuropathic Pain in Mice. Toxins (Basel) (2016) 0.75
Aqueous extract of Lithospermi radix attenuates oxaliplatin-induced neurotoxicity in both in vitro and in vivo models. BMC Complement Altern Med (2016) 0.75
Cetuximab-induced hypomagnesaemia aggravates peripheral sensory neurotoxicity caused by oxaliplatin. J Gastrointest Oncol (2010) 0.75
Granulomatous lung disease requiring mechanical ventilation induced by a single application of oxaliplatin-based chemotherapy for colorectal cancer: a case report. Case Rep Oncol Med (2013) 0.75
A pH responsive complexation-based drug delivery system for oxaliplatin. Chem Sci (2017) 0.75
Emotional Responses to Persistent Chemotherapy-induced Peripheral Neuropathy Experienced by Patients with Colorectal Cancer in Japan. Asia Pac J Oncol Nurs (2017) 0.75
[Evaluating the benefits of mammographic breast cancer screening]. Orv Hetil (2010) 2.02
Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med (2007) 2.00
Current issues in adjuvant treatment of stage II colon cancer. Ann Surg Oncol (2006) 1.85
Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist (2010) 1.52
2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer. Pediatr Blood Cancer (2009) 1.39
Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer. Int J Radiat Oncol Biol Phys (2008) 1.34
18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. Cancer Biother Radiopharm (2009) 1.22
The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study. J Nucl Med (2011) 1.13
A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials. Invest New Drugs (2011) 1.07
Chemotherapy for metastatic breast cancer-report of a European expert panel. Lancet Oncol (2002) 1.06
Should FDG PET/CT be used for the initial staging of breast cancer? Eur J Nucl Med Mol Imaging (2009) 1.00
Combination of topotecan and oxaliplatin in inoperable hepatocellular cancer patients. Am J Clin Oncol (2002) 0.87
Docetaxel in advanced gastric cancer. Anticancer Drugs (2002) 0.87
Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients. Clin Cancer Res (2004) 0.86
[Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer]. Bull Cancer (2007) 0.84
Prognostic significance of a combined clinicopathologic score for response to primary systemic therapy in locally advanced breast cancer. Oncol Rep (2005) 0.82
Gemcitabine-oxaliplatin combination in heavily pretreated metastatic breast cancer: a pilot study on 43 patients. Breast J (2007) 0.79
Follicular dendritic cell tumor of the mediastinum: expression of fractalkine and SDF-1alpha as mast cell chemoattractants. Virchows Arch (2006) 0.78
Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer? Oncologist (2002) 0.78
Characterization and multiparameter analysis of visual adverse events in irofulven single-agent phase I and II trials. Clin Cancer Res (2004) 0.78
[Clinical practice guidelines: Standards, Options and Recommendations for first line medical treatment of patients with ovarian neoplasms (summary report)]. Bull Cancer (2004) 0.77
Prospective, double-blind, randomized trial of equimolar mixture of nitrous oxide/oxygen to prevent pain induced by insertion of venous access ports in cancer patients. Support Care Cancer (2005) 0.76
A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors. Invest New Drugs (2006) 0.76
[Impact of [18F]-FDG-PET on medical decision making in oncology: evaluation by the referring physicians during the opening year]. Bull Cancer (2002) 0.75
[Interests and perspectives of PET-CT for breast cancer: review of the literature]. Bull Cancer (2007) 0.75
[Standards & options: recommendations for the use of erythropoiesis-stimulating agents (ESA) in anaemic cancer patients undergoing radiotherapy (2007 update)]. Cancer Radiother (2008) 0.75
[Clinical Practice guidelines for the use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin bêta, darbepoetin) in anaemic patients with cancer: 2007 update (summary report)]. Bull Cancer (2008) 0.75
Rationale and delineation of a composite index of relative antitumoural efficacy (In-RATE). Crit Rev Oncol Hematol (2007) 0.75
[Efficacy of weekly epoetin Beta in the treatment of chemotherapy-induced anemia in solid tumors]. Therapie (2009) 0.75
[Decision making process in oncology: rationale and delineation of a composite index of relative antitumoral efficacy (In-RATE)]. Bull Cancer (2008) 0.75
[Advanced ovarian cancer: a need for redefining therapeutic objectives and strategy]. Bull Cancer (2005) 0.75
[Node negative breast cancer. Beyond international consensus: a pragmatic approach]. Bull Cancer (2011) 0.75
[History of medical oncology]. Bull Cancer (2013) 0.75
Decision making process in oncology practice: is the information available and what should it consist of? Crit Rev Oncol Hematol (2005) 0.75
[Lung cancers in the elderly]. Bull Cancer (2008) 0.75